| ²é¿´: 1743 | »Ø¸´: 10 | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
PSAר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
|
[½»Á÷]
NDA for tasocitinib to treat RA ÒÑÓÐ5È˲ÎÓë
|
|||
Pfizer Inc. (NYSE FE), New York, N.Y.Product: Tofacitinib (CP-690,550) (formerly tasocitinib) Business: Autoimmune Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1) Description: Oral pan-Janus kinase (JAK) inhibitor An NDA for tofacitinib to treat rheumatoid arthritis (RA) is under FDA review with an Aug. 21 PDUFA date, while an MAA is under review in the EU. The product is also under review in Japan. In a conference call to discuss its 2Q12 earnings, Pfizer said FDA requested additional analysis of data in the NDA for tofacitinib, which the pharma said could cause the agency to extend its review of the product past its PDUFA date. Specifics about the request were not disclosed (see BioCentury, Aug. 6). Tofacitinib also is in Phase III testing to treat moderate to severe plaque psoriasis. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market tofacitinib in Japan for RA and other undisclosed indications |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÐÂÒ©·¢ÏÖ |
» ²ÂÄãϲ»¶
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ130È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ2È˻ظ´
ҩѧר˶É격
ÒѾÓÐ12È˻ظ´
26É격×Ô¼ö
ÒѾÓÐ12È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
¿ÉÄÜÉϲ»Á˰¶£¿ÓÐÌõ¼þµÄ¿ÉÒÔ¿¼ÂÇÆäËû³ö·
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Ïã¸ÛRAǩע°ìÀí×Éѯ
ÒѾÓÐ17È˻ظ´
International Journal for Numerical Methods in Engineering¶þÉóʱ¼ä
ÒѾÓÐ13È˻ظ´
Äõ½ÁËÃÀ¹úÒ»¸ö´óѧµÄOFFER£¬µ«ÊÇÍâµ¼¸øµÄRA²¹Öú²»¹»Éú»î·Ñ
ÒѾÓÐ8È˻ظ´
Ç󱽵ķÖ×Ó¹ìµÀÄܼ¶£¨molecular orbital binding energies for benzene£©
ÒѾÓÐ8È˻ظ´
¡¾the song I want to sing for u¡¿My love by Сè£¨ÖØÔÚ²ÎÓ룩O(¡É_¡É)O~
ÒѾÓÐ94È˻ظ´
Ê׽졾³ªÎÒ×îÏ볪µÄÍâÓï¸èÇú¡¿xxx(the song I want to sing for u)±ÈÈü
ÒѾÓÐ141È˻ظ´
FortranÖйØÓÚÊý×éµÄ±ä»¯
ÒѾÓÐ5È˻ظ´
ÐÂÍþµç³Ø²âÊÔÒÇÔõô´ÓNDAÎļþÖе¼³öEXCELÎļþ£¿
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿Äڵز©Ê¿Ã»±ÏÒµ£¬¿ÉÒÔÉêÇëÀí´óµÄRAÂð£¿
ÒѾÓÐ10È˻ظ´
PSA
ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
- Ó¦Öú: 41 (СѧÉú)
- ¹ó±ö: 0.287
- ½ð±Ò: 6557.6
- É¢½ð: 1295
- ºì»¨: 10
- ɳ·¢: 2
- Ìû×Ó: 1157
- ÔÚÏß: 392.7Сʱ
- ³æºÅ: 685572
- ×¢²á: 2008-12-31
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
|
ÕâÕýÊÇ¿ª·¢ÐÂÒ©µÄ·çÏÕ°É£¬·çÏÕÖл¹ÊÇ´æÔÚ»ú»áµÄ£¡ ¿Ú·þ¸øÒ©£¬ÎÒÏëÓ¦¸ÃÊÇÒ»¸öºÜ´óÓÅÊÆ°É£¡Ò©Ð§Èç¹ûÄܹ»´ïµ½ÖÎÁÆÄ¿µÄ£¬¸öÈ˾õµÃ¾Í¹»ÁË£¬µ«ÊǸ±×÷ÓÃ&²»Á¼·´Ó¦ÊÇÒ»¸öÐèÒª¿¼ÂǵĺÜÑÏÖØÎÊÌâ¡£ pfizerûÁËÁ¢ÆÕÍ×£¬¾Ý˵»¹Ö¸×ÅtofacitinibÄØ£¬¾Ý·ÖÎöʦԤ²â¸ÃÒ©ÎïµÄÊг¡Ç°¾°Ê®·Ö²»´í£¡ ²»ÖªµÀδÀ´»áÔõÑù£¡ ʱ¼ä»á¸æËß´ó¼Ò´ð°¸£¬Ö»ÊÇ»òÔç»òÍí£¡ |
8Â¥2012-08-20 17:41:56
cpujacs
ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)
- Ó¦Öú: 72 (³õÖÐÉú)
- ¹ó±ö: 6.872
- ½ð±Ò: 38795.2
- É¢½ð: 8615
- ºì»¨: 99
- ɳ·¢: 3
- Ìû×Ó: 7486
- ÔÚÏß: 2629.5Сʱ
- ³æºÅ: 292516
- ×¢²á: 2006-11-04
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
- ¹ÜϽ: SciFinder/Reaxys
3Â¥2012-08-20 13:15:10
PSA
ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
- Ó¦Öú: 41 (СѧÉú)
- ¹ó±ö: 0.287
- ½ð±Ò: 6557.6
- É¢½ð: 1295
- ºì»¨: 10
- ɳ·¢: 2
- Ìû×Ó: 1157
- ÔÚÏß: 392.7Сʱ
- ³æºÅ: 685572
- ×¢²á: 2008-12-31
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
4Â¥2012-08-20 13:22:26
PSA
ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)
- Ó¦Öú: 41 (СѧÉú)
- ¹ó±ö: 0.287
- ½ð±Ò: 6557.6
- É¢½ð: 1295
- ºì»¨: 10
- ɳ·¢: 2
- Ìû×Ó: 1157
- ÔÚÏß: 392.7Сʱ
- ³æºÅ: 685572
- ×¢²á: 2008-12-31
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
6Â¥2012-08-20 15:29:08













FE), New York, N.Y.
»Ø¸´´ËÂ¥
50